Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Caris Life Sciences Inc (CAI)

Caris Life Sciences Inc (CAI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Caris Life Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026 PR Newswire - Thu Jul 16, 7:30AM CDT

IRVING, Texas , July 16, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading TechBio company, today announced it will report second quarter 2026 financial results on Wednesday,...

CAI : 15.65 (+1.76%)
Caris Life Sciences Expands Precision Oncology in Metastatic Prostate Cancer with PTEN IHC Testing PR Newswire - Tue Jul 14, 7:30AM CDT

IRVING, Texas , July 14, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced...

CAI : 15.65 (+1.76%)
Caris Life Sciences Announces Dual Listing on NYSE Texas PR Newswire - Tue Jun 16, 7:30AM CDT

IRVING, Texas , June 16, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced...

CAI : 15.65 (+1.76%)
Caris Life Sciences Announces Share Repurchase Program PR Newswire - Mon Jun 8, 7:30AM CDT

IRVING, Texas , June 8, 2026 /PRNewswire/ -- Caris Life Sciences® (Nasdaq: CAI) ("Caris" or the "Company"), a leading next-generation AI TechBio company and precision medicine pioneer, today announced...

CAI : 15.65 (+1.76%)
Caris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris' Comprehensive Genomic Testing PR Newswire - Tue May 26, 7:30AM CDT

Inaugural story spotlights a woman whose presumed stage 4 metastatic breast cancer diagnosis was corrected by Caris GPSai, an AI-powered tissue-of-origin model, revealing a highly treatable lymphoma...

CAI : 15.65 (+1.76%)
A concept image showing a virus attacking blood cells by crystal light via Shutterstock
You’ve Likely Never Heard of Caris Life Sciences Stock. Billionaire Stanley Druckenmiller Has – and He Likes What He Sees. Barchart - Wed May 20, 12:34PM CDT

Caris Life Sciences just earned a $33.87 million vote of confidence from Stanley Druckenmiller, and most people completely missed it.

CAI : 15.65 (+1.76%)
Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris MI Cancer Seek PR Newswire - Fri May 15, 7:30AM CDT

The Caris Lookback Program identified 13,293 patients potentially eligible for newly approved targeted therapies across 10 tumor types

CAI : 15.65 (+1.76%)
MarketBeat.com
Caris Life Sciences Eyes Bigger Oncology Market After IPO as Revenue Jumps 79% MarketBeat - Wed May 13, 4:06AM CDT

Caris Life Sciences (NASDAQ:CAI) executives said the company is expanding its commercial reach, product pipeline and biopharma partnerships as it looks to build on recent revenue growth following its IPO...

CAI : 15.65 (+1.76%)
Caris Life Sciences Publishes Study Showing Whole Exome Measurement of Tumor Mutational Burden Results in Increased Overall Survival Compared to Estimates from Targeted Gene Panels PR Newswire - Mon May 11, 11:15AM CDT

Targeted gene panels miscalculate tumor mutational burden in 10–15% of patients, directly resulting in incorrect pembrolizumab eligibility determination

CAI : 15.65 (+1.76%)
Caris Life Sciences Submits Application to New York State Department of Health for Caris Assure Blood‑Based Testing Authorization PR Newswire - Fri May 8, 3:05PM CDT

IRVING, Texas , May 8, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced...

CAI : 15.65 (+1.76%)

Barchart Exclusives

CapEx Fears Eclipse Alphabet’s Strong Q2, but GOOGL Stock Still Looks Attractive Barchart - 1 hour ago
While GOOGL stock could remain volatile as investors digest elevated spending, Alphabet remains well positioned to benefit from the accelerating AI investment cycle. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.